Back to the Top
Hi,
I am working on a molecule which intended rout of administration is
intra nasal. IC50 for CYP 2D6is less than 5 uM. I am wondering if i.n.
administration implies less liability for drug-drug interaction, in
comparison to p.o. administration.
Thanks
Sinisa
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)